LOAMS
FOLD

Lombard Odier Asset Management (Switzerland)’s Amicus Therapeutics FOLD Stock Holding History

Lombard Odier Asset Management (Switzerland)’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-261,592
Closed -$2.9M – 231
2023
Q1 		$2.9M Buy
+261,592
New +$3.22M 0.25% 95

Other funds holding FOLD

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Lombard Odier Asset Management (Switzerland)'s FOLD Position: Q2 2023 in Review

Lombard Odier Asset Management (Switzerland) sold out of Amicus Therapeutics (FOLD) in Q2 2023, closing a stake of 261,592 shares — an estimated $2.9M sold.

Lombard Odier Asset Management (Switzerland) first reported a position in FOLD in Q1 2023 and held it in 1 quarter. The position peaked at $2.9M in Q1 2023. 216 funds tracked by Wall St. Rank hold FOLD as of Q2 2023.

  • Lombard Odier Asset Management (Switzerland) reported no remaining Amicus Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Lombard Odier Asset Management (Switzerland) sold 261,592 Amicus Therapeutics shares in Q2 2023, an estimated $2.9M.
  • Lombard Odier Asset Management (Switzerland) first reported a position in Amicus Therapeutics in Q1 2023 and held it in 1 quarter.
  • Lombard Odier Asset Management (Switzerland)'s Amicus Therapeutics position peaked at $2.9M in Q1 2023.
  • 216 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q2 2023.

Based on Lombard Odier Asset Management (Switzerland)'s 13F filing for Q2 2023, filed 14 Aug 2023.